Replimune Raises $55 Million to Advance its Oncolytic … – PR Newswire (press release)
Endpoints News |
Replimune Raises $55 Million to Advance its Oncolytic …
PR Newswire (press release) Replimune Group Inc., a biotechnology company focused on developing next generation oncolytic immunotherapies, announced today the completion of a $55 … Replimune Appoints Howard L. Kaufman, M.D., FACS as Chief … |
